ArticleNeurology(R) neuroimmunology & neuroinflammation2023
More Efficient Complement Activation by Anti-Aquaporin-4 Compared With Anti-Myelin Oligodendrocyte Glycoprotein Antibodies.
Open access · goldAbstract readComparative Study
In one paragraph
Article in Neurology(R) neuroimmunology & neuroinflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 33 citations in OpenAlex.
- B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity.Annals of clinical and translational neurology · 2024Trial
- Human Autoantibodies Against MOG Isoforms: α3 Antibodies Suggest Relapsing Disease Course in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Antibody-Dependent Cellular Phagocytosis and Cytotoxicity in Patients With LGI1 and CASPR2 Encephalitis.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- The Comprehensive Live Cell-Based Cytotoxicity Assay for Monitoring Disease Activity and Guiding Rescue Therapy in Acute Attacks of NMOSD.Annals of clinical and translational neurology · 2026Article
- Characteristic patterns of complement deposition in NMOSD, MOGAD, and MS.Acta neuropathologica · 2026Article
- Patient-Derived Monoclonal Myelin Oligodendrocyte Glycoprotein Autoantibodies Mediate Cytotoxicity.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Inflammatory transcriptomic signatures in a human cellular NMOSD model reveal upregulation of NF-κB and IL6 pathways.Scientific reports · 2025Article
- MOGAD: A Shifting Landscape-From Pathogenesis to Personalised Management, Global Perspectives and Latin American Insights.Biomedicines · 2025Review
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Pathophysiology, Clinical Patterns, and Therapeutic Challenges of Intractable and Severe Forms.International journal of molecular sciences · 2025Review
- Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks.Journal of neurology, neurosurgery, and psychiatry · 2025Article
- Fluid Biomarkers in Demyelinating Spectrum Disorders: Past, Present, and Prospects.International journal of molecular sciences · 2025Review
- Ten Years ofNeurology(R) neuroimmunology & neuroinflammation · 2025Article
- Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Translational insights from EAE models : decoding MOGAD pathogenesis and therapeutic innovation.Frontiers in immunology · 2025Review
- Article
- Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Should We Measure CSF Complement Levels in Patients With MOGAD?Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.Journal of neurology · 2024Review
- Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder.Frontiers in immunology · 2024Article
- Blood-Brain Barrier Breakdown in Neuroinflammation: Current In Vitro Models.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 2 countries.
Magdalena LerchFrom the Clinical Department of Neurology (M.L., K.S., H.H., M.R.), Medical University of Innsbruck, Austria; Institute of Hygiene and Medical Microbiology (E.L., R.W., D.W.), Medical University of Innsbruck, Austria; Neurology Unit (S.M., A.D.), Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Italy; Department of Pediatric Neurology (E.M.W.), Olgahospital/Klinikum Stuttgart, Germany; Department of Pediatrics I (C.L.), Medical University of Innsbruck, Austria; Paediatric Neurology (K.R.), Witten/Herdecke University, Children's Hospital Datteln, Germany; Department of Neurology (T.B.), Medical University of Vienna, Austria; and Division of Neuropathology and Neurochemistry (C.L., R.H.), Department of Neurology, Medical University of Vienna, Austria.
Kathrin SchandaFrom the Clinical Department of Neurology (M.L., K.S., H.H., M.R.), Medical University of Innsbruck, Austria; Institute of Hygiene and Medical Microbiology (E.L., R.W., D.W.), Medical University of Innsbruck, Austria; Neurology Unit (S.M., A.D.), Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Italy; Department of Pediatric Neurology (E.M.W.), Olgahospital/Klinikum Stuttgart, Germany; Department of Pediatrics I (C.L.), Medical University of Innsbruck, Austria; Paediatric Neurology (K.R.), Witten/Herdecke University, Children's Hospital Datteln, Germany; Department of Neurology (T.B.), Medical University of Vienna, Austria; and Division of Neuropathology and Neurochemistry (C.L., R.H.), Department of Neurology, Medical University of Vienna, Austria.
Eliott LafonFrom the Clinical Department of Neurology (M.L., K.S., H.H., M.R.), Medical University of Innsbruck, Austria; Institute of Hygiene and Medical Microbiology (E.L., R.W., D.W.), Medical University of Innsbruck, Austria; Neurology Unit (S.M., A.D.), Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Italy; Department of Pediatric Neurology (E.M.W.), Olgahospital/Klinikum Stuttgart, Germany; Department of Pediatrics I (C.L.), Medical University of Innsbruck, Austria; Paediatric Neurology (K.R.), Witten/Herdecke University, Children's Hospital Datteln, Germany; Department of Neurology (T.B.), Medical University of Vienna, Austria; and Division of Neuropathology and Neurochemistry (C.L., R.H.), Department of Neurology, Medical University of Vienna, Austria.
Reinhard WürznerFrom the Clinical Department of Neurology (M.L., K.S., H.H., M.R.), Medical University of Innsbruck, Austria; Institute of Hygiene and Medical Microbiology (E.L., R.W., D.W.), Medical University of Innsbruck, Austria; Neurology Unit (S.M., A.D.), Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Italy; Department of Pediatric Neurology (E.M.W.), Olgahospital/Klinikum Stuttgart, Germany; Department of Pediatrics I (C.L.), Medical University of Innsbruck, Austria; Paediatric Neurology (K.R.), Witten/Herdecke University, Children's Hospital Datteln, Germany; Department of Neurology (T.B.), Medical University of Vienna, Austria; and Division of Neuropathology and Neurochemistry (C.L., R.H.), Department of Neurology, Medical University of Vienna, Austria.
Sara MariottoFrom the Clinical Department of Neurology (M.L., K.S., H.H., M.R.), Medical University of Innsbruck, Austria; Institute of Hygiene and Medical Microbiology (E.L., R.W., D.W.), Medical University of Innsbruck, Austria; Neurology Unit (S.M., A.D.), Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Italy; Department of Pediatric Neurology (E.M.W.), Olgahospital/Klinikum Stuttgart, Germany; Department of Pediatrics I (C.L.), Medical University of Innsbruck, Austria; Paediatric Neurology (K.R.), Witten/Herdecke University, Children's Hospital Datteln, Germany; Department of Neurology (T.B.), Medical University of Vienna, Austria; and Division of Neuropathology and Neurochemistry (C.L., R.H.), Department of Neurology, Medical University of Vienna, Austria.
Alessandro DinotoFrom the Clinical Department of Neurology (M.L., K.S., H.H., M.R.), Medical University of Innsbruck, Austria; Institute of Hygiene and Medical Microbiology (E.L., R.W., D.W.), Medical University of Innsbruck, Austria; Neurology Unit (S.M., A.D.), Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Italy; Department of Pediatric Neurology (E.M.W.), Olgahospital/Klinikum Stuttgart, Germany; Department of Pediatrics I (C.L.), Medical University of Innsbruck, Austria; Paediatric Neurology (K.R.), Witten/Herdecke University, Children's Hospital Datteln, Germany; Department of Neurology (T.B.), Medical University of Vienna, Austria; and Division of Neuropathology and Neurochemistry (C.L., R.H.), Department of Neurology, Medical University of Vienna, Austria.ORCID 0000-0002-3249-4792
Eva Maria WendelFrom the Clinical Department of Neurology (M.L., K.S., H.H., M.R.), Medical University of Innsbruck, Austria; Institute of Hygiene and Medical Microbiology (E.L., R.W., D.W.), Medical University of Innsbruck, Austria; Neurology Unit (S.M., A.D.), Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Italy; Department of Pediatric Neurology (E.M.W.), Olgahospital/Klinikum Stuttgart, Germany; Department of Pediatrics I (C.L.), Medical University of Innsbruck, Austria; Paediatric Neurology (K.R.), Witten/Herdecke University, Children's Hospital Datteln, Germany; Department of Neurology (T.B.), Medical University of Vienna, Austria; and Division of Neuropathology and Neurochemistry (C.L., R.H.), Department of Neurology, Medical University of Vienna, Austria.
Christian LechnerFrom the Clinical Department of Neurology (M.L., K.S., H.H., M.R.), Medical University of Innsbruck, Austria; Institute of Hygiene and Medical Microbiology (E.L., R.W., D.W.), Medical University of Innsbruck, Austria; Neurology Unit (S.M., A.D.), Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Italy; Department of Pediatric Neurology (E.M.W.), Olgahospital/Klinikum Stuttgart, Germany; Department of Pediatrics I (C.L.), Medical University of Innsbruck, Austria; Paediatric Neurology (K.R.), Witten/Herdecke University, Children's Hospital Datteln, Germany; Department of Neurology (T.B.), Medical University of Vienna, Austria; and Division of Neuropathology and Neurochemistry (C.L., R.H.), Department of Neurology, Medical University of Vienna, Austria.
Harald HegenFrom the Clinical Department of Neurology (M.L., K.S., H.H., M.R.), Medical University of Innsbruck, Austria; Institute of Hygiene and Medical Microbiology (E.L., R.W., D.W.), Medical University of Innsbruck, Austria; Neurology Unit (S.M., A.D.), Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Italy; Department of Pediatric Neurology (E.M.W.), Olgahospital/Klinikum Stuttgart, Germany; Department of Pediatrics I (C.L.), Medical University of Innsbruck, Austria; Paediatric Neurology (K.R.), Witten/Herdecke University, Children's Hospital Datteln, Germany; Department of Neurology (T.B.), Medical University of Vienna, Austria; and Division of Neuropathology and Neurochemistry (C.L., R.H.), Department of Neurology, Medical University of Vienna, Austria.
Kevin RostásyFrom the Clinical Department of Neurology (M.L., K.S., H.H., M.R.), Medical University of Innsbruck, Austria; Institute of Hygiene and Medical Microbiology (E.L., R.W., D.W.), Medical University of Innsbruck, Austria; Neurology Unit (S.M., A.D.), Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Italy; Department of Pediatric Neurology (E.M.W.), Olgahospital/Klinikum Stuttgart, Germany; Department of Pediatrics I (C.L.), Medical University of Innsbruck, Austria; Paediatric Neurology (K.R.), Witten/Herdecke University, Children's Hospital Datteln, Germany; Department of Neurology (T.B.), Medical University of Vienna, Austria; and Division of Neuropathology and Neurochemistry (C.L., R.H.), Department of Neurology, Medical University of Vienna, Austria.
Thomas BergerFrom the Clinical Department of Neurology (M.L., K.S., H.H., M.R.), Medical University of Innsbruck, Austria; Institute of Hygiene and Medical Microbiology (E.L., R.W., D.W.), Medical University of Innsbruck, Austria; Neurology Unit (S.M., A.D.), Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Italy; Department of Pediatric Neurology (E.M.W.), Olgahospital/Klinikum Stuttgart, Germany; Department of Pediatrics I (C.L.), Medical University of Innsbruck, Austria; Paediatric Neurology (K.R.), Witten/Herdecke University, Children's Hospital Datteln, Germany; Department of Neurology (T.B.), Medical University of Vienna, Austria; and Division of Neuropathology and Neurochemistry (C.L., R.H.), Department of Neurology, Medical University of Vienna, Austria.
Doris WilflingsederFrom the Clinical Department of Neurology (M.L., K.S., H.H., M.R.), Medical University of Innsbruck, Austria; Institute of Hygiene and Medical Microbiology (E.L., R.W., D.W.), Medical University of Innsbruck, Austria; Neurology Unit (S.M., A.D.), Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Italy; Department of Pediatric Neurology (E.M.W.), Olgahospital/Klinikum Stuttgart, Germany; Department of Pediatrics I (C.L.), Medical University of Innsbruck, Austria; Paediatric Neurology (K.R.), Witten/Herdecke University, Children's Hospital Datteln, Germany; Department of Neurology (T.B.), Medical University of Vienna, Austria; and Division of Neuropathology and Neurochemistry (C.L., R.H.), Department of Neurology, Medical University of Vienna, Austria.
Romana HöftbergerFrom the Clinical Department of Neurology (M.L., K.S., H.H., M.R.), Medical University of Innsbruck, Austria; Institute of Hygiene and Medical Microbiology (E.L., R.W., D.W.), Medical University of Innsbruck, Austria; Neurology Unit (S.M., A.D.), Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Italy; Department of Pediatric Neurology (E.M.W.), Olgahospital/Klinikum Stuttgart, Germany; Department of Pediatrics I (C.L.), Medical University of Innsbruck, Austria; Paediatric Neurology (K.R.), Witten/Herdecke University, Children's Hospital Datteln, Germany; Department of Neurology (T.B.), Medical University of Vienna, Austria; and Division of Neuropathology and Neurochemistry (C.L., R.H.), Department of Neurology, Medical University of Vienna, Austria.
Markus ReindlFrom the Clinical Department of Neurology (M.L., K.S., H.H., M.R.), Medical University of Innsbruck, Austria; Institute of Hygiene and Medical Microbiology (E.L., R.W., D.W.), Medical University of Innsbruck, Austria; Neurology Unit (S.M., A.D.), Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Italy; Department of Pediatric Neurology (E.M.W.), Olgahospital/Klinikum Stuttgart, Germany; Department of Pediatrics I (C.L.), Medical University of Innsbruck, Austria; Paediatric Neurology (K.R.), Witten/Herdecke University, Children's Hospital Datteln, Germany; Department of Neurology (T.B.), Medical University of Vienna, Austria; and Division of Neuropathology and Neurochemistry (C.L., R.H.), Department of Neurology, Medical University of Vienna, Austria. markus.reindl@i-med.ac.at.ORCID 0000-0003-2817-1402
Innsbruck Medical University · AT
Funding
Austrian Science Fund FWF P 32699
Abstract
BACKGROUND AND
objectivesThe objective was to study complement-mediated cytotoxicity induced by immunoglobulin G (IgG) anti-aquaporin-4 antibodies (AQP4-IgG) and anti-myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) in human serum samples from patients suffering from the rare demyelinating diseases of the CNS neuromyelitis optica spectrum disorder (NMOSD) and MOG-IgG-associated disease (MOGAD).
methodsA cell-based assay with HEK293A cells expressing different MOG isoforms (MOGα
resultsAQP4-IgG-positive serum samples induced higher CDC and TCC levels than MOG-IgG-positive sera. Notably, both showed a correlation between antibody titers and CDC and also between titers and TCC levels. In addition, all 6 MOG isoforms tested (MOGα DISCUSSION: Both MOG-IgG and AQP4-IgG are able to induce CDC in a titer-dependent manner. However, AQP4-IgG showed markedly higher levels of CDC compared with MOG in vitro on target cells. This further highlights the role of complement in AQP4-IgG-mediated disease and diminishes the importance of complement activation in MOG-IgG-mediated autoimmune disease.
Indexed as
Aquaporin 4AutoantibodiesComplement ActivationHumansImmunoglobulin GMyelin-Oligodendrocyte GlycoproteinOligodendrogliaAquaporin 4AutoantibodiesImmunoglobulin GMyelin-Oligodendrocyte Glycoprotein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.